The new NVM5 v2.0 platform "hosts a comprehensive set of intraoperative technologies specifically designed for spine surgery, including the sensory monitoring modality (SSEP) for multimodality monitoring of the spinal cord and peripheral nerves, as well as refinements to the recently launched spinal rod-bending technology called Bendini," NuVasive said.
The platform helps surgeons avoid nerves during extreme lateral interbody fusion procedures while navigating the psoas major muscle in the lower back, according to a press release. The system also gives "nerve proximity" data during the placement of pedicle cannulae and screws, according to the release, and provides nerve root, spinal cord and peripheral sensory nerve monitoring.
NVM5 V2.0 leverages the experience that NuVasive has accumulated through the past 12 years, with more than 250,000 spine surgeries utilizing the Company’s proprietary monitoring platform.
"NVM5 version 2.0 demonstrates our continued commitment to developing innovative, adjunctive technologies that assist in the safety and reproducibility of surgical outcomes for spine patients, while also improving operating room economics," global products and services president Pat Miles said in prepared remarks.
In May, NuVasive won a patent row with Cadwell Laboratories over the patents underlying the NVM5 technology, with the lab agreeing to exit the lateral spine business and pay a 5% royalty on any future Cadwell products that use the technology.
The spat with Cadwell involved the same technology that handed NuVasive its only win in another patent infringement case with Medtronic (NYSE:MDT) in September 2011. A federal jury in San Diego issued a split verdict in that case, awarding $101.2 million to Medtronic and $660,000 to its smaller spine rival, finding that Medtronic’s NIM-Eclipse System infringed a patent covering the NVM5 system.